Could Tesla still rally? It depends on who you ask. So TheStreet did just that.
The carmaker will receive a cash infusion as its focuses on value creation and self-driving vehicles.
The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.
After taking an undisclosed stake in Birchbox, Walgreens is hoping that beauty sales can help drive growth and make the company more defensible.
The problems at GE are all about hubris and hurt feelings.
A decade ago, amid an economic boom in "emerging markets" like Brazil, Russia, India and China, the Teacher Retirement System of Texas decided to plow nearly 10% of all savings into stocks from the countries. Now, the teachers are reeling from the mistake, with subpar returns and outsize risks that could have been easily avoided had the fund just stuck with large U.S. stocks.
This week's go-private move by Sonic Corp. extends a run of restaurant deals that probably isn't over.